INTRODUCES CARBOHYDRATE ANTIGEN 19-9 RADIOIMMUNOASSAY

A VALUABLE RESEARCH TOOL USING MONOCLONAL ANTIBODIES FOR DETECTION AND MANAGEMENT OF GASTROINTESTINAL CANCERS

CA 19-9™ RIA is an in vitro radioimmunoassay for the measurement of CA 19-9™ in serum or plasma.

THIS NEW TUMOR MARKER HAS DEMONSTRATED...

...LOW FALSE POSITIVE RATES
- Normal Population < 0.5%
- Heavy Smokers < 1.8%
- Pancreatitis, rectal polyps and inflammatory bowel disease < 3%

...HIGH ASSOCIATION WITH GI CANCERS
- High sensitivity and specificity for pancreatic cancer.
- Improved performance for detection of pancreatic, liver and stomach cancers.

...USEFULNESS AS A PROGNOSTIC MONITOR FOR COLORECTAL CANCER
- Clinical studies indicate CA 19-9™ levels may be elevated in some patients 6 to 18 months prior to Carcinoembryonic Antigen for the prediction of colorectal cancer recurrence.
- CA 19-9™ provides additional as well as confirmatory information for prognostic management of colorectal cancer patients when paired with Carcinoembryonic Antigen.

...POTENTIAL TO BROADEN THE SCOPE OF CANCER RESEARCH
- This new tumor marker which is sensitive for gastrointestinal malignancies and with low false positive rates affords a new tool for studies in such areas as chemotherapy protocols or testing of cancer diagnostics.

CA 19-9™ RIA IS AVAILABLE FOR RESEARCH USE.

HOW TO ORDER:
By phone: (800) 345-2401 Continental USA.
(800) 342-2842 PA only.
(215) 296-4488 All others.
By telex: 834823 MARN
By mail: CENTOCOR, Inc., 244 Great Valley Parkway, Malvern, PA 19355 USA
IT TOOK US 20 YEARS TO GET THE DIAGNOSTIC RESULTS WE WANTED. IT'LL ONLY TAKE YOU 10 DAYS.

Waiting up to 4 weeks for diagnostic results could be the end of your experiment. Fortunately, you have an alternative. It's Charles River Biotechnical Services, Inc.

A newly formed subsidiary of Charles River Breeding Laboratories, Inc., CRBS functions independently and professionally in its diagnostic operations, servicing the biomedical research community at large as well as its parent company.

FAST RESULTS CAN'T HAPPEN OVERNIGHT.

It took 20 years of supporting the world's leading breeder of laboratory animals to get where we are today. But it's this experience that now allows us to guarantee we'll put the written results from your samples in the mail to you within 10 working days of receipt.

Or phone results within 5 working days, if you use our priority service.

UNCOVERING THE MEANING BEHIND THE RESULTS.

Getting accurate results is every researcher's prime concern. However, it's equally important for researchers to understand the results they get. CRBS is in a unique position to provide this important information when required. First of all, we have the laboratory experience. Each year we perform over 250,000 serological and bacteriological tests with unmatched accuracy.

Whether you require our Assessment Profile or Tracking Profiles, we'll execute them for you fast and accurately.

But most significantly, only CRBS goes well beyond laboratory procedures. Our unequaled staff of professionals can assist you with interpretation and evaluation of results as well in virology, immunology, bacteriology, parasitology, pathology and laboratory animal medicine.

PROTECTING YOUR EXPERIMENT'S FUTURE WITH GENETIC MONITORING.

At CRBS, we believe it's vital to learn the genetic integrity of your mice both before and during your experiment. That's why we also offer you genetic monitoring of inbred, hybrid, and congenic mice.

Through use of electrophoretic technology, we can determine the appropriate biochemical markers of the strains used today.

In addition to this, we provide genetic monitoring with immunogenetic markers, including H-2, Lyb-2, Lyt-1, Lyt-2, Thyl, and Tla.

So if you're looking for results with complete accuracy and without unnecessary waiting, come to CRBS. Because we don't think you should have to experiment with providers of diagnostic services.
Spontaneous regressions of clinically overt cancer in man are rare events, intriguing and challenging. For indeed, if we understood the mechanisms involved, an important step would have been taken toward our mastery over the inexorable progression of neoplastic disease.

The first step, however, is a critical evaluation of the reported cases of spontaneous regressions of cancer. This task was undertaken by Drs. Tilden C. Everson and Warren H. Cole, of the University of Illinois College of Medicine, and published in 1966 by W. B. Saunders of Philadelphia as "Spontaneous Regression of Cancer."

Dr. Everson was born in 1920 and obtained his doctorate from the University of Minnesota School of Medicine in 1943. He has been clinical professor of surgery at Illinois since 1963. He is pictured on the left.

Dr. Warren H. Cole was born in 1898 and was graduated from Washington University School of Medicine in 1920. He was professor of surgery and head of the department at Illinois from 1936 until his retirement in 1967.

The authors gathered cases from the world literature and personal communications. Each case was critically evaluated, and 176 were accepted as examples of spontaneous regression.

Of 176 cases, over half were represented by 4 entities: hypernephroma; neuroblastoma; malignant melanoma; and choriocarcinoma. Presented from this material is Case 26, of a child with multiple subcutaneous metastases of neuroblastoma, and histological sections of a nodule at initial diagnosis and of a regressive nodule 4 months later. (This case was originally reported by G. Mülke and O. Hornstein, Z. Kinderheilk, 83: 40, 1959.)

We are indebted to Drs. Everson (left) and Cole (right) for their portraits and to Dr. Everson for permission to reproduce the neuroblastoma report.

M.B.S.